How does Edluar compare to Ambien for treating insomnia. What are the key differences in sleep onset and effectiveness between sublingual and oral zolpidem. How do patients rate Edluar for insomnia treatment.

Overview of Edluar and Its Use for Insomnia

Edluar is a sublingual formulation of zolpidem, a medication commonly used to treat insomnia. It belongs to the class of drugs known as sedative-hypnotics. Edluar is designed to be placed under the tongue where it dissolves rapidly, allowing for faster absorption into the bloodstream compared to oral tablets.

According to user reviews on Drugs.com, Edluar has an impressive average rating of 9.2 out of 10 for the treatment of insomnia, based on 12 reviews. A substantial 92% of reviewers reported a positive experience with Edluar, while no users reported negative experiences.

How Does Edluar Work?

Edluar works by enhancing the activity of GABA, a neurotransmitter that promotes sleep and relaxation in the brain. By binding to GABA receptors, zolpidem increases sleepiness and helps initiate sleep more quickly. The sublingual formulation allows for rapid absorption through the oral mucosa, potentially leading to a faster onset of action compared to traditional oral tablets.

Edluar vs Ambien: Key Differences

While Edluar and Ambien both contain the active ingredient zolpidem, there are some important differences between these two insomnia medications:

• Formulation: Edluar is a sublingual tablet, while Ambien is an oral tablet
• Absorption: Edluar is absorbed more rapidly through the oral mucosa
• Onset of action: Edluar may have a faster onset due to its sublingual delivery
• Administration: Edluar dissolves under the tongue, Ambien is swallowed with water

Is Sublingual Zolpidem More Effective Than Oral Zolpidem?

A randomized controlled trial published in Current Medical Research and Opinion compared sublingual zolpidem (Edluar) 10 mg to oral zolpidem (Ambien) 10 mg in patients with primary insomnia. The study found that sublingual zolpidem significantly shortened latency to persistent sleep (LPS) by 34% or 10.3 minutes compared to oral zolpidem. This suggests that the sublingual formulation may indeed lead to faster sleep onset.

Patient Reviews and Experiences with Edluar

Based on the Drugs.com reviews, patients generally report very positive experiences with Edluar for treating insomnia:

• 58% of reviewers gave Edluar a perfect 10/10 rating
• 17% rated it 9/10
• 17% rated it 8/10
• 8% rated it 7/10

No reviewers gave Edluar a rating below 7/10, indicating a high level of satisfaction among users. Many patients likely appreciate the fast-acting nature of the sublingual formulation for quickly inducing sleep.

Effectiveness of Edluar for Sleep Onset and Maintenance

The clinical study comparing sublingual and oral zolpidem provides insight into Edluar’s effectiveness for sleep onset:

• Latency to persistent sleep (LPS) was reduced by 34% with sublingual zolpidem
• Sleep onset latency (SOL) was also significantly shortened
• Latency to stage 1 sleep (ST1L) was reduced with sublingual zolpidem

These findings suggest that Edluar may be particularly effective for helping patients fall asleep more quickly. However, the study did not find significant differences in sleep maintenance or total sleep time between the two formulations.

Does Edluar Help with Middle-of-the-Night Awakenings?

While Edluar is primarily designed for sleep onset, some patients may find it helpful for middle-of-the-night awakenings due to its rapid absorption. However, it’s important to have at least 4 hours of sleep time remaining before using Edluar in the middle of the night to avoid next-day impairment. Patients should consult their healthcare provider about the appropriate use of Edluar for their specific sleep issues.

Safety Considerations and Side Effects of Edluar

As with all sleep medications, Edluar carries potential risks and side effects that patients should be aware of:

• Drowsiness and dizziness, especially in the morning
• Headache
• Nausea or upset stomach
• Dry mouth
• Potential for dependence or abuse
• Risk of complex sleep behaviors (e.g., sleep-walking, sleep-driving)

Patients should only use Edluar as directed by their healthcare provider and for short-term treatment of insomnia. Long-term use of zolpidem-containing medications may lead to tolerance or dependence.

Are There Any Specific Precautions for Using Sublingual Zolpidem?

When using Edluar, patients should be aware of the following precautions:

• Do not eat, drink, or smoke while the tablet is dissolving
• Avoid alcohol and other CNS depressants while using Edluar
• Do not drive or perform hazardous activities for at least 4 hours after taking Edluar
• Inform your doctor of all medications you are taking to avoid potential interactions

Comparing Edluar to Other Insomnia Treatments

While Edluar has shown effectiveness for many patients, it’s important to consider how it compares to other insomnia treatments:

• Cognitive Behavioral Therapy for Insomnia (CBT-I): A non-pharmacological approach that can be highly effective for long-term insomnia management
• Other Z-drugs: Medications like eszopiclone (Lunesta) or zaleplon (Sonata) may have different durations of action
• Melatonin receptor agonists: Drugs like ramelteon (Rozerem) work differently and may have fewer side effects
• Orexin receptor antagonists: Newer medications like suvorexant (Belsomra) or lemborexant (Dayvigo) offer a different mechanism of action

The choice of insomnia treatment should be made in consultation with a healthcare provider, considering the individual patient’s sleep patterns, medical history, and preferences.

Tips for Maximizing the Effectiveness of Edluar

To get the most benefit from Edluar while minimizing risks, consider the following tips:

1. Take Edluar only when you have a full night (7-8 hours) to devote to sleep
2. Create a relaxing bedtime routine to complement the medication’s effects
3. Avoid caffeine, alcohol, and large meals close to bedtime
4. Keep your bedroom cool, dark, and quiet
5. Use Edluar as part of a comprehensive sleep hygiene plan
6. Follow up regularly with your healthcare provider to assess the ongoing need for medication

How Can Patients Transition Off Edluar Safely?

If you’ve been using Edluar regularly and wish to discontinue use, it’s crucial to work with your healthcare provider on a tapering plan. Abrupt discontinuation of zolpidem can lead to rebound insomnia or withdrawal symptoms in some patients. A gradual reduction in dose, combined with implementation of good sleep hygiene practices and possibly CBT-I, can help ensure a smooth transition off the medication.

Future Directions in Insomnia Treatment

As research in sleep medicine progresses, new approaches to insomnia treatment are emerging:

• Digital therapeutics: FDA-approved apps for delivering CBT-I
• Personalized medicine: Tailoring treatments based on genetic or biomarker profiles
• Novel drug targets: Exploring new neurotransmitter systems involved in sleep regulation
• Combination therapies: Integrating pharmacological and non-pharmacological approaches

While Edluar represents an important option in the current landscape of insomnia treatments, ongoing research may lead to even more effective and personalized approaches in the future.

What Role Might Artificial Intelligence Play in Future Insomnia Management?

Artificial intelligence (AI) is poised to play an increasingly important role in insomnia management. AI algorithms could potentially analyze sleep patterns from wearable devices, providing personalized recommendations for sleep hygiene and medication timing. Additionally, AI-powered chatbots could deliver cognitive behavioral therapy for insomnia, making this effective treatment more accessible to a wider population.

As we look to the future of insomnia treatment, it’s clear that a multi-faceted approach combining pharmacological options like Edluar with innovative technologies and personalized interventions will likely provide the best outcomes for patients struggling with sleep disorders.

Edluar for Insomnia Reviews – Drugs.com

Print

Save

Edluar
has an average rating of 9.2 out of 10 from a total of 12 reviews
for the
treatment of Insomnia.
92% of reviewers reported a positive experience, while 0% reported a negative experience.

Edluar rating summary

9.2/10 average rating

12 ratings from 13 user reviews.

Compare all 83 medications used in the treatment of Insomnia.

Reviews for Edluar

Frequently asked questions

• Quviviq vs. Ambien: How do they compare?
• Ambien: What are 11 Things You Need to Know?
• Why am I unable to sleep after taking Ambien?
• Is Ambien safe for long-term use?

Are you taking this medicine?

• Add your review
• Learn more about Edluar

More FAQ

• Is Ambien a benzo?
• Is Ambien addictive?
• What is this pill? Tannish peach color, elliptical, marked 10 MG and 5 dots in a small box?
• What is the half life of Ambien?

Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.

Learn more about Insomnia

• Anticholinergic Drugs to Avoid in the Elderly
• Benzodiazepines: Overview and Use
• Sleep (Insomnia) Medications and Alcohol Interactions

Care guides

• Insomnia

Symptoms and treatments

• Insomnia

Medicine.

com guides (external)

• Insomnia Guide

More about Edluar (zolpidem)

• Check interactions
• Compare alternatives
• Pricing & coupons
• Drug images
• Latest FDA alerts (4)
• Side effects
• Dosage information
• During pregnancy
• Generic availability
• FDA approval history
• Drug class: miscellaneous anxiolytics, sedatives and hypnotics
• Breastfeeding
• En español

Patient resources

• Drug Information

Other brands

Ambien, Ambien CR, Zolpimist, Intermezzo

Professional resources

• Prescribing Information

Related treatment guides

• Insomnia

Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia

Randomized Controlled Trial

. 2010 Jun;26(6):1423-31.

doi: 10. 1185/03007991003788225.

Corinne Staner 
¹
, Frédéric Joly, Nathalie Jacquot, Irina D Vlasova, Maria Nehlin, Thomas Lundqvist, Charlotte Edenius, Luc Staner

Affiliations

Affiliation

• ¹ Forenap Pharma, Rouffach, France.

• PMID:

  20397964

• DOI:

  10.1185/03007991003788225

Randomized Controlled Trial

Corinne Staner et al.

Curr Med Res Opin.

2010 Jun.

. 2010 Jun;26(6):1423-31.

doi: 10.1185/03007991003788225.

Authors

Corinne Staner 
¹
, Frédéric Joly, Nathalie Jacquot, Irina D Vlasova, Maria Nehlin, Thomas Lundqvist, Charlotte Edenius, Luc Staner

Affiliation

• ¹ Forenap Pharma, Rouffach, France.

• PMID:

  20397964

• DOI:

  10.1185/03007991003788225

Abstract

Objective:

To compare the hypnotic effects of a single dose of a sublingual formulation of zolpidem (Edluar*) 10 mg vs oral formulation (Ambien dagger ) 10 mg by polysomnography (PSG) in DSM-IV primary insomnia patients. Primary objective was to compare the two formulations on sleep induction, measured by latency to persistent sleep (LPS), sleep onset latency (SOL) and latency to stage 1 (ST1L).

Research and methods:

This was a randomized, double-blind, two-period, cross-over multi-centre study in which each period comprised two successive PSG recording nights. Treatment was administered when PSG recordings started. Subjective sleep and residual effects were assessed the next morning.

Results:

Seventy female and male patients aged 19-64 were analysed. Sublingual zolpidem significantly shortened LPS by 34% or 10.3 minutes as compared to oral zolpidem (95% CI: -4.3 min to -16.2 min, p = 0.001). SOL and ST1L were also significantly shortened (p < 0.01). Furthermore the two formulations were comparable in terms of sleep maintenance properties based on total sleep time (TST). The improvement in subjective sleep and next-day residual effects did not differ between the two treatments. Both routes of administration were well tolerated.

Conclusions:

The results demonstrate that sublingual zolpidem is superior to an equivalent dose of oral zolpidem in terms of sleep inducing properties in a carefully selected sample of primary insomnia patients.

Similar articles

• Sublingual zolpidem (Edluar™; Sublinox™).

  Yang LP, Deeks ED.

  Yang LP, et al.
  CNS Drugs. 2012 Nov;26(11):1003-10. doi: 10.1007/s40263-012-0009-y.
  CNS Drugs. 2012.

  PMID: 23034583

  Review.

• Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study.

  Staner L, Eriksson M, Cornette F, Santoro F, Muscat N, Luthinger R, Roth T.

  Staner L, et al.
  Sleep Med. 2009 Jun;10(6):616-20. doi: 10.1016/j.sleep.2008.06.008. Epub 2008 Nov 8.
  Sleep Med. 2009.

  PMID: 18996742

  Clinical Trial.

• Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

  Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group.

  Roth T, et al.
  Sleep Med. 2006 Aug;7(5):397-406. doi: 10.1016/j.sleep.2006.04.008. Epub 2006 Jul 3.
  Sleep Med. 2006.

  PMID: 16815744

  Clinical Trial.

• Lower doses of sublingual Zolpidem are more effective than oral Zolpidem to anticipate sleep onset in healthy volunteers.

  Valente KD, Hasan R, Tavares SM, Gattaz WF.

  Valente KD, et al.
  Sleep Med. 2013 Jan;14(1):20-3. doi: 10.1016/j.sleep.2012.09.003. Epub 2012 Dec 4.
  Sleep Med. 2013.

  PMID: 23218533

  Clinical Trial.

• A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia.

  Staner L, Danjou P, Luthringer R.

  Staner L, et al.
  Expert Rev Neurother. 2012 Feb;12(2):141-53. doi: 10.1586/ern.11.197.
  Expert Rev Neurother. 2012.

  PMID: 22288669

  Review.

See all similar articles

Cited by

• Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial.

  Castro LS, Otuyama LJ, Fumo-Dos-Santos C, Tufik S, Poyares D.

  Castro LS, et al.
  Braz J Psychiatry. 2020 Apr;42(2):175-184. doi: 10.1590/1516-4446-2019-0389. Epub 2019 Dec 20.
  Braz J Psychiatry. 2020.

  PMID: 31859791
  Free PMC article.

  Clinical Trial.

• Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.

  Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL.

  Sateia MJ, et al.